The U.S. Blood System: Under Pressure
Dr. Menitove discusses obstacles and pressure on U.S. blood centers and the U.S. blood supply.
Targeted Therapy to Trigger GVL: A Case for the Prosecution in FLT3-ITD–Mutant AML
Dr. Roberts sheds light on a mechanism by which a small molecule inhibitor targeting a leukemia-specific kinase mutation can trigger an effective CD8 T cell-mediated allo-i
A number of publications from 2014 that impact our understanding and treatment of multiple myeloma (MM) stand out. First, insights into the mechanism of action of thalidomide and its analogues came fast and frequently. With more direct therapeutic relevance, the results of the Phase III ASPIRE clinical trial were published. This trial tested the hypothesis that three drugs would be better than two in relapsed MM. Finally, a randomized trial reconfirmed the role of transplantation in MM patients younger than 65 years.
May-June 2018Volume 15, Issue 3
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology